Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Wedbush

Wedbush assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report sent to investors on Friday morning, MarketBeat.com reports. The firm issued an outperform rating and a $18.00 price target on the stock.

A number of other equities research analysts have also issued reports on the stock. BTIG Research assumed coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. HC Wainwright assumed coverage on Avalo Therapeutics in a report on Thursday, October 24th. They issued a “neutral” rating for the company.

Avalo Therapeutics Stock Up 17.9 %

AVTX opened at $8.44 on Friday. Avalo Therapeutics has a 12-month low of $4.20 and a 12-month high of $34.46. The firm’s fifty day moving average price is $7.82 and its 200 day moving average price is $9.40.

Institutional Trading of Avalo Therapeutics

Several institutional investors have recently added to or reduced their stakes in AVTX. RA Capital Management L.P. acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at about $9,186,000. Ikarian Capital LLC lifted its holdings in Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after acquiring an additional 915,629 shares during the last quarter. Northern Trust Corp acquired a new position in Avalo Therapeutics in the fourth quarter valued at approximately $168,000. Velan Capital Investment Management LP bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at approximately $817,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the period. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.